Crossover trials are clinical experiments in which participants are assigned randomly to a sequence of treatments and each participant serves as his/her own control in estimating the treatments’ effect.

The advantage of crossover is that it effectively doubles the number of people in a trial which makes it easier to obtain statistically significant results more quickly, and participants act as their own control since their data is analyzed by comparing participants to themselves – before the intervention and after each intervention period.

Essentially, the study participants are switched through the treatment groups (both test and reference formulations) after a washout period. This gives a greater set of results with fewer volunteers and in a more controlled way.

QUINTA-ANALYTICA who are experts in this approach go a step further and plan and design studies so that the washout period of one study is utilized as a confinement period for another. Combine this with the fact they’ve smartly constructed their clinical unit in two independent parts to allow for simultaneous studies, the outcome is an impressive set of quality results in a very short period.

Ready to start your next cross-over Bioavailability or Bioequivalence study? Get in touch!

Additional News

  • 3 September 2026

    Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients

    New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.